Biotech and Pharma Industry News | BioPharma Dive
WEBCell and gene therapy investment, once booming, is now in a slump. Far fewer venture funding rounds were closed by cell and gene therapy developers over the first six months of 2024 than in prior years. Experts say there are several factors. BioPharma Dive provides news and analysis for biotech and biopharmaceutical executives.
Biotech M&A is on the upswing. Here are the latest deals.
WEBAug 13, 2024 · Even neuroscience, which large drugmakers previously abandoned, is drawing investment again. BioPharma Dive is tracking M&A activity below. The database, which shows drugmaker buyouts that have happened since 2018 and were valued at $50 million or more in upfront consideration, will be regularly updated. Click on an acquiring company to pull up ...
First-of-its-kind Type 1 diabetes drug wins FDA approval
WEBNov 18, 2022 · The drug, which will be sold under the name Tzield, is the first treatment cleared by the FDA to delay the onset of Type 1 diabetes. It is approved for individuals over the age of 8 who are considered to be in stage 2 of the autoimmune disease. The agency based its approval on data from a study in 2019 that showed patients with stage 2 Type 1 ...
Pfizer buys sickle cell drugmaker Global Blood for $5.4B
WEBAug 8, 2022 · Pfizer on Monday said it has agreed to acquire Global Blood Therapeutics for $5.4 billion in a deal that will hand it a recently approved drug for sickle cell disease, as well as two other experimental medicines for the rare blood condition.. Under terms of the deal, Pfizer will pay $68.50 in cash per Global Blood share, a premium of 7% over Friday’s closing price for the California company ...
Chasing Novo and Lilly: The obesity drugs that could challenge …
WEBApr 30, 2024 · One study can start a pharmaceutical revolution. Four years ago, a large clinical trial run by Novo Nordisk showed a drug called semaglutide helped people with obesity lose, on average, around 15% of their weight.The results far exceeded what prior studies of other treatments had suggested was possible pharmaceutically, sparking a rush to research that has quickly reshaped the obesity drug field.
Meso Scale Discovery (MSD): An immunoassay platform with …
WEBFeb 22, 2022 · ADVANTAGES. Sensitivity, Range and Ease-of-Use: In comparison to a conventional ELISA, MSD has higher sensitivity (LLOD 0.1-1.4 pg/mL) and a larger dynamic detection range (0.1-10 pg/mL).In addition, MSD has an efficient low volume sampling (1-25 μ L) and minimized matrix effect aiding in simultaneous multiplex detection with high precision. . Furthermore, MSD has simpler protocols, reduced ...
Gilead breaks through with first approval for new HIV drug
WEBAug 22, 2022 · Dive Brief: Gilead’s long-acting HIV shot Sunlenca is now cleared for sale in Europe, marking the first marketing authorization for a treatment the California biotechnology company hopes can be used broadly as a standard therapy and preventive regimen. The decision by the European Commission, announced Monday, authorizes Sunlenca for patients ...
The next era of Greater Boston’s biotech boom | BioPharma Dive
WEBNov 22, 2022 · The next era of Greater Boston’s biotech boom. Over the past two decades, the Cambridge area has become a nerve center for biotech in the U.S. But to stay relevant and accessible, the hub is expanding to the suburbs. Published November 22, 2022 • By Karissa Waddick , Shaun Lucas and Julia Himmel. A map of the Kendall Square neighborhood in ...
Biotech IPOs are the industry’s lifeblood. Track how they’re …
WEB3 days ago · IPO activity reached a peak in 2021, when more than 100 biotechs priced an initial offering and together raised nearly $15 billion. But that momentum came to a halt as 2021 turned to 2022, and stock prices of newly public companies plummeted amid a sector-wide downturn. The pace of IPOs stalled and, last year, only 19 drugmakers priced initial ...
Ferring wins FDA approval for bladder cancer gene therapy
WEBDec 19, 2022 · After years of testing and an initial rejection from the Food and Drug Administration, Ferring Pharmaceuticals on Friday won U.S. approval of its gene therapy for a form of high-risk bladder cancer. Bladder cancer is one of the most common forms of cancer. Most newly diagnosed cases are classified as non-muscle invasive bladder cancer, or …